CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Recombinant and Autologous Platelet-Derived Growth Factors for Wound Healing and Other Non-Orthopedic Conditions

Policy governs coverage of autologous platelet-rich plasma (PRP) for wound healing and other non-orthopedic conditions for Medicare Advantage and Commercial products; specifies Medicare Advantage coverage for chronic non-healing diabetic wounds under certain conditions and noncoverage for other indications and for commercial members.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyRecombinant and Autologous Platelet-Derived Growth Factors for Wound Healing and Other Non-Orthopedic Conditions

Policy CodePolicy N/A

Change TypeProvider Update (April 2026)

Effective DateFeb 1, 2026

Next Review Date

Key ActionWhen billing Medicare Advantage for covered autologous PRP for chronic non-healing diabetic wounds, submit G0465 with the appropriate covered diagnosis code and documentation that the device used is FDA-cleared for management of exuding cutaneous wounds.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes noted in this update.

1Medicare-covered Indication (diabetic chronic wounds)

1HCPCS codes listed

Not medically necessaryCommercial coverage stance

Coverage Summary

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Scope: This policy governs coverage of autologous platelet-rich plasma (PRP) for wound healing and other non‑orthopedic conditions for Medicare Advantage and Commercial products. Coverage stance: mixed — Medicare Advantage covers autologous PRP for chronic non‑healing diabetic wounds when filed with a covered diagnosis and prepared by FDA‑cleared devices for exuding cutaneous wounds; all other indications are either determined by local MACs for Medicare or considered not medically necessary for Commercial products. Effective date: 02/01/2026. Last review: 02/18/2026.

Key policy facts

PayerBlue Cross Blue Shield - Rhode Island

SubjectAutologous platelet-rich plasma (PRP) for wound healing and other non-orthopedic conditions

Coverage stanceMixed (Medicare Advantage: covered for diabetic chronic wounds when filed with a covered diagnosis; Commercial: not medically necessary)

Medicare-covered indication count1

HCPCS codes listed1 (G0465)

Commercial coverage stanceCommercial: not medically necessary

Effective date / Last review dateEffective: 2026-02-01; Last review: 2026-02-18

Medical Necessity / Coverage Criteria

Medicare Advantage - Covered Indication

Autologous PRP is covered for the treatment of chronic non-healing diabetic wounds when filed with a covered diagnosis and prepared by FDA-cleared devices for exuding cutaneous wounds.

Treatment is autologous platelet-rich plasma (PRP)
Wound is a chronic non-healing diabetic wound/ulcer
PRP is prepared by devices whose FDA-cleared indications include the management of exuding cutaneous wounds (such as diabetic ulcers)

Medicare Advantage - Other Chronic Wounds

Coverage determination for other chronic non-healing wounds.

Autologous PRP for treatment of chronic non-healing wounds other than diabetic wounds
Coverage will be determined by local Medicare Administrative Contractors (MACs).

Commercial Products - Not Medically Necessary

Autologous PRP is considered not medically necessary for the following when evidence is insufficient:

Acute wounds (including surgical or traumatic wounds)
Chronic wounds including nonhealing ulcers (including diabetic ulcers, pressure ulcers, venous stasis ulcers)
Use of platelet-rich plasma (autologous blood-derived preparations) for treatment of acute or chronic wounds

Provider Actions & Billing Guidance

Documentation Required

File G0465 with covered diagnosis for Medicare Advantage

When billing Medicare Advantage for covered autologous PRP for chronic non-healing diabetic wounds, submit HCPCS G0465 with an appropriate covered diagnosis and documentation that the device used is FDA-cleared for management of exuding cutaneous wounds. Required documentation should demonstrate the covered diagnosis and that the PRP was prepared using an FDA-cleared device with indications including management of exuding cutaneous wounds (such as diabetic ulcers).

Affected code: G0465
Documentation elements: appropriate covered diagnosis for chronic non-healing diabetic wound; evidence that device used is FDA-cleared for management of exuding cutaneous wounds (eg, diabetic ulcers)

Billing Rule

Medicare coverage duration constraint

Medicare Advantage coverage for autologous PRP for chronic non-healing diabetic wounds is provided for a duration of 20 weeks. Coverage of autologous PRP for these diabetic wounds beyond 20 weeks is determined by local Medicare Administrative Contractors (MACs).

20 weeks
MACs determine beyond 20 weeks

Denial Risk

Commercial claims will be denied as not medically necessary

For Commercial products, the use of platelet-rich plasma for acute or chronic wounds (including surgical wounds and nonhealing ulcers) is considered not medically necessary and commercial claims for these indications may be denied.

Affected codes: G0465
Affected codes: G0460

Background & Evidence

Background: PRP contains platelet‑derived growth factors (eg, PDGF, transforming growth factors, VEGF) thought to aid wound healing; autologous platelet concentrate suspended in plasma is prepared from centrifuged autologous blood and, when activated (eg, thrombin and calcium chloride), releases growth factors and can form a platelet gel for application to wounds. Evidence summary: systematic reviews, meta‑analyses, and multiple small controlled trials have evaluated PRP for chronic wounds with mixed results. For diabetic lower‑extremity ulcers, some meta‑analyses and trials demonstrated improved complete wound closure and healing time, but studies have moderate‑to‑high risk of bias and imprecision limiting conclusions about other outcomes (recurrence, infection, amputation, quality of life). For venous and pressure ulcers and for acute surgical/traumatic wounds, results are mixed or show no clear benefit on important outcomes, and overall the evidence is insufficient to determine net health benefit for many wound types.

Evidence	Summary
CMS NCD
CMS covers autologous PRP for chronic non-healing diabetic wounds under specified device and duration conditions (NCD CAG-00190R4; decision memo 2021); coverage beyond 20 weeks determined by local MACs.
Systematic reviews/meta-analyses
Meta-analyses and systematic reviews show benefit for diabetic lower-extremity ulcers for outcomes like complete wound closure and faster healing time, but studies have risk of bias and imprecision; evidence is insufficient for many other wound types and outcomes.

Definition: Autologous PRP is an autologous platelet concentrate suspended in plasma prepared from centrifuged autologous blood and applied as platelet‑rich plasma or platelet gel.

Name	Number	Effective
Blood-Derived Products for Chronic Non-Healing Wounds
270.3 / CAG-00190R4
2021-04

Revision History

2021-04medicare_ncd_effective

CMS national coverage determination (CAG-00190R4 / Blood-Derived Products for Chronic Non-Healing Wounds) published covering autologous PRP for chronic non-healing diabetic wounds under specified device and duration conditions.

2026-02-01policy_effective

Policy effective date for Medical Coverage Policy: Recombinant and Autologous Platelet-Derived Growth Factors for Wound Healing and Other Non-Orthopedic Conditions.

2026-02-18policy_last_reviewLatest

Policy last reviewed (most recent review date).

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyRecombinant and Autologous Platelet-Derived Growth Factors for Wound Healing and Other Non-Orthopedic Conditions

Policy CodePolicy N/A

Change TypeProvider Update (April 2026)

Effective DateFeb 1, 2026

Next Review Date

SourceLink

On This Page

OpenPayer

Recombinant and Autologous Platelet-Derived Growth Factors for Wound Healing and Other Non-Orthopedic Conditions

Coverage Summary

Medical Necessity / Coverage Criteria

Coding

Provider Actions & Billing Guidance

Background & Evidence

Medicare Determinations

Revision History